{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/restless-legs-syndrome/prescribing-information/rotigotine/","result":{"pageContext":{"chapter":{"id":"1a0b2fc3-18c3-51a9-968c-88bb51f2637f","slug":"rotigotine","fullItemName":"Rotigotine","depth":2,"htmlHeader":"<!-- begin field 94b5d0ad-c7c3-435e-9bb1-b5d30241c5d9 --><h2>Rotigotine</h2><!-- end field 94b5d0ad-c7c3-435e-9bb1-b5d30241c5d9 -->","summary":"","htmlStringContent":"<!-- begin item 85e2dbe4-dd89-4608-9c57-e8e95b3bf288 --><!-- end item 85e2dbe4-dd89-4608-9c57-e8e95b3bf288 -->","topic":{"id":"ce2c49b0-9c88-5bbe-b742-179c3a41de7d","topicId":"8560b6b4-74c4-48fb-99b2-1738f7bdfc1c","topicName":"Restless legs syndrome","slug":"restless-legs-syndrome","lastRevised":"Last revised in November 2020","chapters":[{"id":"0c5685ed-e78f-5c68-8983-83a722c74100","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6a7ab99-3bce-5334-8352-694d31ef5cc0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"461085e4-b723-57af-8f1a-16da6b5276cd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8a4d8c25-f2fc-5706-989b-f6210f6e1fb8","slug":"changes","fullItemName":"Changes"},{"id":"08d30779-72aa-5609-89bb-35fa111203a1","slug":"update","fullItemName":"Update"}]},{"id":"8544bde0-46f9-502a-aec7-2a5a2d449009","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c04c9edd-95d7-5e3f-94ea-5c7ecd6205a8","slug":"goals","fullItemName":"Goals"},{"id":"4d33d470-bfd2-518f-aebb-b9e86daa02ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ab4dd298-08f9-5497-81cd-0ab7e978b675","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8d907e60-5b96-5b39-a188-b481acc2935a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"330f64fa-36dd-5bd9-847c-b379cdd7b437","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9a4d2e02-acae-5411-92f3-bca31ce98b25","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"877ed575-950a-5933-ae1f-abcee48927b8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"623e0c19-8a9e-5892-b3f3-a72ab9d617ce","slug":"definition","fullItemName":"Definition"},{"id":"f6fe6742-330a-5aea-8b52-b32fc2b3ab48","slug":"causes","fullItemName":"Causes"},{"id":"7a8e05a8-1db9-5aac-9b56-c5be8e7eb9d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"86293e20-8427-58da-8512-93f22162d764","slug":"prognosis","fullItemName":"Prognosis"},{"id":"043ee2a1-37c5-5b2f-8d10-0a9d2d41abe0","slug":"complications","fullItemName":"Complications"}]},{"id":"0ef4212f-c56f-508b-897c-741bceff55bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6836b996-4eee-5e2a-a99b-84973696e8e3","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5ccc9458-1b9d-5fa7-a565-2b00a539b9bd","slug":"assessment","fullItemName":"Assessment"},{"id":"729e434c-5849-59fb-b3ca-e7a86f26a8d6","slug":"investigations","fullItemName":"Investigations"},{"id":"0ce4b1b3-2e3a-5901-8e9c-981cea4198d7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7a12e175-49ce-5c68-9c8f-756159646a3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"33ccae89-80e7-572a-b148-a81c781d0956","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3af6c6-eb78-5674-a94f-f5f087e5f812","slug":"pramipexole","fullItemName":"Pramipexole"},{"id":"1664194f-800a-54c6-bd79-106678653aaa","slug":"ropinirole","fullItemName":"Ropinirole"},{"id":"1a0b2fc3-18c3-51a9-968c-88bb51f2637f","slug":"rotigotine","fullItemName":"Rotigotine"},{"id":"87f55f71-dd3d-5e97-9c88-5fe3a78503db","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"a931371b-564c-5833-b5b4-d21ad3f1a361","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"6590cad9-132e-548c-b7ad-bf4375ef2caf","slug":"codeine","fullItemName":"Codeine"},{"id":"70676cc9-d1a4-5639-a227-62e452e13b2b","slug":"benzodiazepines-z-drugs","fullItemName":"Benzodiazepines and Z-drugs"},{"id":"fe9dc2de-9fbe-527f-b34b-446254f3d127","slug":"augmentation","fullItemName":"Augmentation"},{"id":"2203998a-e9f3-59c3-9132-50418bf47566","slug":"loss-of-efficacy","fullItemName":"Loss of efficacy"},{"id":"7d279d8d-8d6c-5c7d-8597-6ee343a7a574","slug":"impulse-control-disorders","fullItemName":"Impulse control disorders"}]},{"id":"0fadb6b8-91c2-57be-8c1d-2d3e31da6d60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"afa91ee5-1f42-5cc6-b9ec-6ef16749457d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"baf472ab-f0f9-518a-8310-81583fd7d905","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9d31c719-7426-52cb-8343-b11a7bb8b5b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a915b18c-93a0-5269-8ff1-021677ba9dd3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e85726f-b5ea-5c2c-a886-f74ab46fbc6b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8ac2285b-b086-5b54-98d6-0ec8c43f05c2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a058ec2-b2e0-5618-b51f-27102b964d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"cc06cb3b-ee07-5de8-b047-ed874422b097","slug":"doses","fullItemName":"Doses","depth":3,"htmlHeader":"<!-- begin field 24f4fee5-0ed0-4fb4-b011-f80906e67fdf --><h3>What doses of rotigotine are indicated for restless legs syndrome?</h3><!-- end field 24f4fee5-0ed0-4fb4-b011-f80906e67fdf -->","summary":"","htmlStringContent":"<!-- begin item 40a6093a-0ae9-4afb-b517-27f053cccd8a --><!-- begin field fc23317d-9084-48f1-b55d-997b46aebddc --><ul><li><strong>Initial dose:</strong> rotigotine patch 1 mg/24 hours.</li><li><strong>Titration:</strong> increase if needed by 1 mg/24 hours weekly if required.</li><li><strong>Maximum recommended dose:</strong> 3 mg/24 hours.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020d</a>]</p><!-- end field fc23317d-9084-48f1-b55d-997b46aebddc --><!-- end item 40a6093a-0ae9-4afb-b517-27f053cccd8a -->","subChapters":[]},{"id":"817bfe1b-14ff-5f6a-b042-f5bd2d39ea70","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 20357fa7-61f7-4543-9e70-acde853e67ae --><h3>What are the contraindications for rotigotine?</h3><!-- end field 20357fa7-61f7-4543-9e70-acde853e67ae -->","summary":"","htmlStringContent":"<!-- begin item 252328c4-f5a8-4eda-a0a0-5da0648bfe9b --><!-- begin field 8946c061-64e8-40a5-800c-a0bc16556fe4 --><ul><li><strong>Do not prescribe rotigotine for restless legs syndrome to:</strong><ul><li>Pregnant or breastfeeding women.</li><li>People with hypersensitivity to rotigotine or to any constituent in the tablet.</li></ul></li><li><strong>Magnetic resonance imaging and cardioversion:</strong><ul><li>The backing layer of rotigotine patch contains aluminium. To avoid skin burns, the patch should be removed if the person has to undergo magnetic resonance imaging (MRI) or cardioversion.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field 8946c061-64e8-40a5-800c-a0bc16556fe4 --><!-- end item 252328c4-f5a8-4eda-a0a0-5da0648bfe9b -->","subChapters":[]},{"id":"28d62e82-ab73-5b3a-ad97-d9025d5d8653","slug":"cautions","fullItemName":"Cautions","depth":3,"htmlHeader":"<!-- begin field d6508fe8-ee2a-4fd4-a8a5-7d31fdd29c57 --><h3>What are the cautions when using rotigotine?</h3><!-- end field d6508fe8-ee2a-4fd4-a8a5-7d31fdd29c57 -->","summary":"","htmlStringContent":"<!-- begin item 58ffd59f-75e3-49c9-a4a2-9833e87c13ce --><!-- begin field 04c78613-309e-4b2e-af5c-02590d2564c4 --><ul><li><strong>Driving and using machinery</strong><ul><li>Rotigotine causes somnolence and episodes of sudden sleep onset in some people, and, uncommonly, without awareness or warning.</li><li>People should exercise caution while driving or operating machines, and must not drive or operate machinery if they experience episodes of sudden sleep onset.</li><li>The dose should be reduced or the drug stopped completely if sudden sleep onset occurs.</li><li>Also, exercise caution if taking other sedating drugs or alcohol in combination with rotigotine.</li></ul></li><li><strong>Psychotic disorders</strong><ul><li>Mania, delirium, and hallucinations may occur in people treated with rotigotine.</li><li>People with psychotic disorders should only be treated with rotigotine if the potential benefits outweigh the risks.</li><li>Co-administration of antipsychotic drugs with rotigotine should be avoided.</li></ul></li><li><strong>Visual disturbances</strong><ul><li>Visual disturbances such as double vision and difficulty focussing have been reported. The manufacturers of rotigotine recommend ophthalmologic monitoring at regular intervals or if vision abnormalities occur.</li></ul></li><li><strong>People with severe cardiovascular disease</strong><ul><li>Blood pressure monitoring, especially at the beginning of treatment, is recommended owing to the risk of postural hypotension associated with dopaminergic therapy.</li></ul></li><li><strong>Heat application</strong><ul><li>External heat (such as excessive sunlight, heating pads, saunas, hot baths) should not be applied to the area of the patch.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field 04c78613-309e-4b2e-af5c-02590d2564c4 --><!-- end item 58ffd59f-75e3-49c9-a4a2-9833e87c13ce -->","subChapters":[]},{"id":"d9885db4-5b2a-5cd9-8bb7-06a350335532","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field cb07bb22-bc06-438d-8cd2-f816488c1d97 --><h3>What drug interactions interactions are associated with rotigotine?</h3><!-- end field cb07bb22-bc06-438d-8cd2-f816488c1d97 -->","summary":"","htmlStringContent":"<!-- begin item 8b6eb9a3-1119-4fb6-9e9f-f3393c245d2f --><!-- begin field d3b38cd0-75d8-4787-9604-caa82fdd8d60 --><ul><li><strong>The manufacturer of rotigotine advises avoiding concomitant use of antipsychotic drugs </strong>owing to an antagonism of effect.</li><li><strong>Metoclopramide:</strong> the manufacturer of rotigotine advises avoiding concomitant use of metoclopramide owing to an antagonism of effect.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Preston, 2020</a>]</p><!-- end field d3b38cd0-75d8-4787-9604-caa82fdd8d60 --><!-- end item 8b6eb9a3-1119-4fb6-9e9f-f3393c245d2f -->","subChapters":[]},{"id":"e1e767c4-3067-59c1-b269-b139f008fff1","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f57e3ed5-fc55-4d4f-8b13-5a9a37183a9d --><h3>What are the adverse effects of rotigotine?</h3><!-- end field f57e3ed5-fc55-4d4f-8b13-5a9a37183a9d -->","summary":"","htmlStringContent":"<!-- begin item ad3d142f-c636-45b6-9253-a85db0e01b40 --><!-- begin field a02bb2dd-da33-4508-baec-6f36056bd181 --><ul><li><strong>The most commonly reported adverse drug reactions </strong>in people with restless legs syndrome treated with rotigotine patch are nausea, headache, and skin reactions to the patch.<ul><li>Skin reactions to the patch include: erythema, pruritus, irritation, dermatitis, vesicles, pain, inflammation, swelling, discolouration, papules, exfoliation, urticaria, and hypersensitivity.</li><li>Rotating the site of patch application can reduce the risk of skin reactions.</li></ul></li><li><strong>Less common but important adverse drug reactions </strong>include hallucinations, delusions, confusion, obsessive-compulsive disorder, sudden somnolence or drowsiness, visual disturbances, <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/augmentation/\">augmentation</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/impulse-control-disorders/\">impulse control disorders</a>.</li><li><strong>Dopamine dysregulation syndrome </strong>has been observed during post-marketing, but the frequency is unknown.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field a02bb2dd-da33-4508-baec-6f36056bd181 --><!-- end item ad3d142f-c636-45b6-9253-a85db0e01b40 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}